🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,609 results for “AB” Clear

  1. Omega-3 fatty acids

    NORTHWEST BIOTHERAPEUTICS INC

    Metabolic Syndrome X

    phase 1 other active

    1 trial

  2. Onartuzumab

    Hoffmann-La Roche

    Carcinoma, Hepatocellular

    phase 1 small molecule completed

    1 trial

  3. Ontamalimab

    Takeda

    Steatohepatitis

    phase 1 small molecule terminated

    1 trial

  4. Open label, Phase I study to assess and compare the pharmacokinetic parameters after multiple oral administration of stiripentol 1000 mg in renal impaired patients and matching controls with normal renal function

    Biocodex

    Patients with renal impairement

    phase 1 other active

    1 trial

  5. Open label, single-center, cross-over randomized, relative bioavailability study comparing a new pitolisant hydrochloride tablet formulation versus the marketed pitolisant (Wakix®) tablet formulation after single oral administrations in healthy subjects.

    Bioprojet Pharma

    narcolepsy with cataplexy, Narcolepsy

    phase 1 other active

    1 trial

  6. Open label, single-center, cross-over randomized, relative bioavailability study comparing a new pitolisant hydrochloride tablet formulation at 4 different strengths versus the marketed pitolisant (Wakix®) tablet formulation after single oral administrations in healthy subjects

    Bioprojet Pharma

    Narcolepsy, Narcolepsy with cataplexy

    phase 1 other active

    1 trial

  7. Open label, single-center, two-part pharmacokinetic study: Part I: Relative bioavailability study to compare the pharmacokinetics of BP1.4979 after administration of single oral doses of BP1.4979 as sustained release formulation and actual immediate release formulation, under fasting and fed conditions, in healthy subjects. Part II: Pharmacokinetics of BP1.4979 after a 14-day dosing period with b.i.d. administration of BP1.4979 as sustained release formulation in healthy subjects.

    Bioprojet Pharma

    Binge eating disorder

    phase 1 other active

    1 trial

  8. Open-label, non-randomised, single-dose, one sequence, two-period, cross-over study to investigate the effect of inhibition of P-glycoprotein and breast cancer resistance protein transporters by cyclosporine on the pharmacokinetics of CHF6001 in healthy volunteers.

    Chiesi Farmaceutici S.p.A

    Chronic obstructive pulmonary disease

    phase 1 other active

    1 trial

  9. Open-label, randomized, two-treatment, two-period, two-sequence, cross-over, single dose, bioequivalence study comparing ISOPRINOSINE® FORTE 100 mg/mL Syrup to ISOPRINOSINE® 500 mg tablets in healthy male and female subjects under fasting conditions.

    Lacuna Pharma Pty Ltd

    not applicable (submitted trial is a bioequivalence study)

    phase 1 other active

    1 trial

  10. Optical PD-L1 imaging using Quantitative Fluorescence Endoscopy in locally advanced esophageal cancer using durvalumab-680LT: a phase I multicenter feasibility and safety study

    Disc Medicine

    Esophageal cancer

    phase 1 other active

    1 trial

  11. Oshadi Oral Insulin

    BRIGHT MINDS BIOSCIENCES INC.

    Diabetes

    phase 1 small molecule completed

    1 trial

  12. OxyCODONE 5 mg Oral Tablet

    BRIGHT MINDS BIOSCIENCES INC.

    Pain

    phase 1 small molecule active

    1 trial

  13. Oxycodone Medication First

    BRIGHT MINDS BIOSCIENCES INC.

    Prescription Drug Abuse (Not Dependent)

    phase 1 small molecule completed

    1 trial

  14. PAS-004 Tablets

    Pasithea Therapeutics

    NF1 Mutation

    phase 1 small molecule active

    1 trial

  15. PCS6422 and capecitabine

    Processa Pharmaceuticals

    Advanced Cancer

    phase 1 small molecule completed

    1 trial

  16. PEGPH20

    HALOZYME THERAPEUTICS, INC.

    Cholangiocarcinoma Non-resectable

    phase 1 small molecule terminated

    1 trial

  17. PET study of changes in [11C]AZ14132516 uptake following administration of multiple AZD7798 doses to patients with Crohn’s disease.

    AstraZeneca AB

    Crohn's disease

    phase 1 other active

    1 trial

  18. PET-imaging of two Vartumabs (F8scFv and C9scFv) in patients with solid tumors – a Phase 0 basket trial

    Lacuna Pharma Pty Ltd

    Multiple solid tumors including: colorectal carcinoma (CRC), pancreatic carcinoma, oesophageal or gastric carcinoma, head and neck squamous cell carcinoma (HNSCC), chondrosarcoma or osteosarcoma, bladder carcinoma, lung carcinoma and glioblastoma.

    phase 1 other active

    1 trial

  19. PF-05190457

    Pfizer

    Diabetes Mellitus, Type 2

    phase 1 small molecule completed

    1 trial

  20. PIVEKIMAB SUNIRINE

    AbbVie Deutschland GmbH & Co. KG

    Relapsed or Refractory Acute Myeloid Leukemia; Acute Myeloid Leukemia, Acute Myeloid Leukemia

    phase 1 small molecule active

    1 trial

  21. Pantoprazole Sodium 40 mg delayed-release tablets

    Teva Pharma GmbH

    Healthy

    phase 1 small molecule completed

    2 trials

  22. Paracetamol 1000mg Tablets, Diphenhydramin-Hevert Injektionslösung, Diphenhydramine Hydrochloride Tablets 25 mg, LYNOZYFIC 200 mg concentrate for solution for infusion, LYNOZYFIC 5 mg concentrate for solution for infusion, Dexamethasone 3.3 mg/ml solution for injection/infusion, REGN17372

    Lacuna Pharma Pty Ltd

    Relapsed/Refractory Multiple Myeloma

    phase 1 small molecule active

    1 trial

  23. Pembrolizumab

    United Therapeutics Europe Ltd

    Cervix Cancer

    phase 1 other terminated

    1 trial

  24. Pembrolizumab

    United Therapeutics Europe Ltd

    Thoracic Tumours

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources